Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000623897
Ethics application status
Approved
Date submitted
8/06/2012
Date registered
8/06/2012
Date last updated
2/11/2012
Type of registration
Retrospectively registered

Titles & IDs
Public title
Comparison between the effect of probiotic cheese and probiotic yoghurt on blood lipids in healthy adult volunteers
Scientific title
Comparison between the effect of probiotic cheese and probiotic yoghurt on blood lipids in healthy adult volunteers: a triple blinded randomized trial
Secondary ID [1] 280644 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Blood lipids 286660 0
Condition category
Condition code
Diet and Nutrition 286954 286954 0 0
Other diet and nutrition disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Arm1: 30 g Probiotic feta ultra filtered cheese containing Lactobacillus acidophilus LA5 and Bifidobacterium lactis BB12 with the dosage of 5 × 106 CFU to consume in the daily diet. Duration of consumption: 7 weeks/ everyday Arm2: 100 g Probiotic yoghurt containing Lactobacillus acidophilus LA5 and Bifidobacterium lactis BB12 with the dosage of 5 × 106 CFU to consume in the daily diet. Duration of consumption: 7 weeks/ everyday
Intervention code [1] 285043 0
Prevention
Comparator / control treatment
The control group received no treatment and was compared to the study interventions
Control group
Active

Outcomes
Primary outcome [1] 287296 0
At least 17% reduction in the blood cholesterol level.

Primary outcome method of measurement: Blood sample analysis - enzymatic method with Parsazmun kits (DiaSys, Germany)
Timepoint [1] 287296 0
Before the intervention and 7 weeks after the start of intervention.
Secondary outcome [1] 297852 0
Blood HDL increase.

Method of measurement: Blood sample analysis - direct Clearance method (Randox, UK)
Timepoint [1] 297852 0
Before the intervention and 7 weeks after the start of intervention.
Secondary outcome [2] 297853 0
Blood Triglyceride reduction.

Method of measurement: Blood sample analysis - enzymatic method with Parsazmun kits (DiaSys, Germany)
Timepoint [2] 297853 0
Before the intervention and 7 weeks after the start of intervention.
Secondary outcome [3] 297854 0
Blood LDL reduction.

Method of measurement: Blood sample analysis - enzymatic method with Parsazmun kits (DiaSys, Germany)
Timepoint [3] 297854 0
Before the intervention and 7 weeks after the start of intervention.
Secondary outcome [4] 297855 0
BMI reduction.

Method of measurement:
Body weight (in Kg) was measured with 0.1 Kg accuracy by Seca electronic flat scale (Model 813, Hamburg, Germany).

Heights of the subjects were measured by Seca mechanical measuring tape (model 206, Hamburg, Germany) with 0.1 cm accuracy.
Timepoint [4] 297855 0
Before the intervention and 7 weeks after the start of intervention.

Eligibility
Key inclusion criteria
Healthy condition, aged 18-65, not being lactose intolerance
and willingness to participate in the study.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Smoking, alcohol consumption during the study, pregnancy or breast feeding, being a professional athlete, taking supplements or any sort of drugs specially antibiotics, consumed any Probiotic product during the last month before the intervention start, having kidney or inflammatory intestinal diseases, having thyroid disorders, having any liver or immunodeficiency diseases.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be maintained until the end of the study by using sequentially numbered, opaque, sealed envelopes (SNOSE) method
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
SAS version 9.2 (SAS Institute Inc, Cary, NC, USA) software will be used for randomization. Qualified participants will randomly assign into three groups at a 1:1:1 ratio. Stratified blocked randomization with the stratification factors sex, BMI and age, will be used.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
2/04/2012
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
180
Accrual to date
Final
Recruitment outside Australia
Country [1] 4356 0
Iran, Islamic Republic Of
State/province [1] 4356 0

Funding & Sponsors
Funding source category [1] 285410 0
Self funded/Unfunded
Name [1] 285410 0
Country [1] 285410 0
Iran, Islamic Republic Of
Primary sponsor type
Other
Name
Omega Research Team (ORT)
Address
Number 7-block 5-shahid Hashemi nejad-Lavizan
Tehran

Postal code: 1678813134
Country
Iran, Islamic Republic Of
Secondary sponsor category [1] 284262 0
None
Name [1] 284262 0
Address [1] 284262 0
Country [1] 284262 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 287424 0
The university which the researcher are a member of does not include an ethics committee since it does not have a Medical School. It should be noted that all the standard ethical procedures about the human subject were completely considered.
Ethics committee address [1] 287424 0
Ethics committee country [1] 287424 0
Date submitted for ethics approval [1] 287424 0
08/06/2012
Approval date [1] 287424 0
Ethics approval number [1] 287424 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 34289 0
Address 34289 0
Country 34289 0
Phone 34289 0
Fax 34289 0
Email 34289 0
Contact person for public queries
Name 17536 0
Shayan Mohammad Moradi
Address 17536 0
Number 7-block 5-shahid Hashemi nejad-Lavizan
Tehran

Postal code: 1678813134
Country 17536 0
Iran, Islamic Republic Of
Phone 17536 0
+98 912 3582980
Fax 17536 0
Email 17536 0
shayan.m.moradi@omegart.org
Contact person for scientific queries
Name 8464 0
Shayan Mohammad Moradi
Address 8464 0
Number 7-block 5-shahid Hashemi nejad-Lavizan
Tehran

Postal code: 1678813134
Country 8464 0
Iran, Islamic Republic Of
Phone 8464 0
+98 912 3582980
Fax 8464 0
Email 8464 0
shayan.m.moradi@omegart.org

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.